Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 15/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21434044 | 0.86 | EPHX2 (0.53) | CHRM4EPHX2CHRM2 | |
| SCHEMBL21433969 | 0.80 | CHRM4 (0.51) | CHRM4EPHX2CHRM2CHRM1 | |
| SCHEMBL21433966 | 0.75 | CHRM2 (0.49) | CHRM4EPHX2CHRM2CHRM1 | |
| SCHEMBL21434009 | 0.75 | CHRM2 (0.46) | CHRM4EPHX2CHRM2CHRM1 | |
| SCHEMBL21433995 | 0.74 | MALT1 (0.47) | CHRM4EPHX2CHRM2CHRM1 | |
| SCHEMBL23992150 | 0.72 | KIT (0.39) | — | |
| SCHEMBL21434094 | 0.71 | CHRM2 (0.49) | CHRM4EPHX2CHRM2CHRM1 | |
| SCHEMBL21433994 | 0.70 | HPGDS (0.43) | CHRM1 | |
| SCHEMBL21434050 | 0.70 | SMPD3 (0.47) | EPHX2 | |
| SCHEMBL20556164 | 0.69 | CHRM4 (0.72) | CHRM4CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | CHRM4 369/4885EPHX2 2087/4885CHRM2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.